As the Society for Immunotherapy of Cancer (SITC) annual meeting kicks off in Houston, we are honored that SUPLEXA, Alloplex Biotherapeutics’ groundbreaking immunotherapy platform, has been recognized among the Top 100 presentations. This recognition speaks to SUPLEXA’s potential as a new approa...
Category: Research
- November 6, 2024
Join Us at SITC 2024 to Discover SUPLEXA’s Breakthrough Potential in Cancer Immunotherapy.
- October 24, 2024
Adapting to Immuno-Oncology’s R&D Challenges: Refocusing on Innate Immunity as a “Next Big Thing” in Cancer Immunotherapy
Dr. Borriello was a featured speaker at a live webinar entitled “Adapting to Immuno-Oncology’s R&D Challenges: Refocusing on Innate Immunity as the ‘Next Big Thing’ in Cancer Immunotherapy”. The live webinar, moderated by Lumanity, brought together a diver...
- April 29, 2022
Alloplex Biotherapeutics announces opening of first clinical trial site
Phase 1 trial of autologous SUPLEXA cell immunotherapy, commences in Adelaide South Australia
Alloplex Biotherapeutics announced today the site opening for its first-in-human clinical trial of SUPLEXA. SUPLEXA therapy is a highly-differentiated, autologous, non-engineered, multi-cellular therapy derived, from patient peripheral blood mononuclear cells. This Phase 1 is a first-in-human, open-...
- April 11, 2022
Alloplex SUPLEXA cells resist immunosuppressive action of two inhibitory cytokines typically found in tumor microenvironment
On April 12, 2022, Jim Lederer, MD, Chief Scientific Officer of Alloplex Biotherapeutics Inc. will present a Poster at the AACR 2022 Annual Meeting in New Orleans, Louisiana: AACR Abstract: IL-10/TGFβ Abstract Control Number: 3599 Title: Interleukin-10 and transforming growth factor-beta do not sup...
- November 15, 2021
Alloplex presents poster describing novel tumor-killing cells at SITC 2021 Conference
Non-engineered SUPLEXA cells demonstrate potent activity against patient-derived cancer organoids in vitro.
Today Alloplex Biotherapeutics released details of its abstract entitled Potent Tumor Organoid Infiltration and Killing by PBMC-Derived Effector Cells presented at SITC 2021. Alloplex’s abstract shows that the organization can generate tumor-killing cells from PBMCs using a clinical grade manufact...